Related Experiment Videos

The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy

Kristen K Reynolds1, Bronwyn Ramey-Hartung, Saeed A Jortani

  • 1PG(XL) Laboratories, 201 E. Jefferson Street, Suite 309, Louisville, KY 40202, USA. kreynolds@pgxlab.com

Clinics in Laboratory Medicine
|December 9, 2008
PubMed

Insights

Managing serious pain involves opioid risks and personalized medicine. Pharmacogenetic biomarkers like CYP2D6 and OPRM1 may improve pain treatment efficacy and safety by assessing patient risk for adverse events.

Area of Science:

  • Pharmacology
  • Genetics
  • Pain Management

Background:

  • Over 80 million Americans suffer from serious pain annually, presenting clinical challenges in treatment selection.
  • Opioid pharmacotherapy is a cornerstone of pain management but carries risks of toxicity, addiction, and adverse reactions.
  • Fear of addiction can lead to undertreatment, highlighting the need for improved patient risk assessment.

Purpose of the Study:

  • To explore the role of opioid pharmacotherapy in pain management.
  • To discuss the risks associated with opioid use, including toxicity and addiction.
  • To examine the potential of pharmacogenetic biomarkers in personalizing pain management strategies.

Main Methods:

  • Review of current literature on pain management and opioid pharmacotherapy.
  • Discussion of pharmacogenetic biomarkers, specifically CYP2D6 and OPRM1.
  • Exploration of the integration of novel diagnostics in clinical practice.

Main Results:

  • Opioid use in pain management is complex, with significant risks.
  • Pharmacogenetic biomarkers (CYP2D6, OPRM1) show promise in predicting patient response and risk.
  • Personalized medicine approaches, utilizing these biomarkers, can potentially enhance treatment efficacy and safety.

Conclusions:

  • Pharmacogenetic biomarkers offer a pathway to personalized pain management.
  • Integrating diagnostics like CYP2D6 and OPRM1 can mitigate opioid risks and improve treatment outcomes.
  • These advancements represent the forefront of personalized medicine in pain management.

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...